2 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TSN084 Treating Patients With Advanced Malignant Tumors TSN084 - Malignant Neoplasm | Phase 1 | Unknown | Tyligand Bioscience (Shanghai) Limited | 114 | 2022-07-20 | 2024-07-29 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents OR2805, Cemiplimab, Docetaxel - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | OncoResponse, Inc. | 172 | 2021-09-09 | 2023-11-02 |
Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Leiomyosarcoma (1) · Liposarcoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Adipose Tissue (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Muscle Tissue (1) · Neoplasms, Nerve Tissue (1)
Docetaxel (1) · cemiplimab (1)
OncoResponse, Inc. (1) · Tyligand Bioscience (Shanghai) Limited (1)
China (1) · United States (1)